Eloxx Pharmaceuticals announced the publication of Phase 2a study results for exaluren in the Journal of Clinical Investigation. The study of three patients demonstrated increased collagen IV abundance and improved podocyte morphology, supporting the ongoing Phase 2b EXACT trial. While the drug was well tolerated with no serious adverse events, clinical measures like proteinuria remained inconsistent.
The Journal of Clinical Investigation publication provides first-in-human proof of mechanism for exaluren: increased collagen IV abundance and partially improved podocyte morphology in all three participants, with no serious adverse events, supporting the ongoing Phase 2b EXACT study. However, the study had only three patients, was open-label, proteinuria changes were inconsistent and hematuria persisted, so the outlook shift is modest rather than decisive.
- ▲ Publication of Phase 2a proof-of-mechanism data in the Journal of Clinical Investigation on Nov. 18, 2026
- ▲ Phase 2b EXACT trial dosing underway since September 2026
- ▼ Only three patients in an open-label study, which the company itself notes is not necessarily predictive of future results
- ▼ Changes in proteinuria were inconsistent and hematuria persisted in all participants